Analyst consensus rating
Definium Therapeutics Analyst Rating: Strong Buy
Direct answer
Definium Therapeutics's consensus rating is Strong Buy.
18 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $72.56.
Forecast evidence checked November 3, 2026.
Get free Definium Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $32.47
- Average price target
- $72.56
- High price target
- $91.00
- Low price target
- $55.00
- Low target gap
- +69.4%
- Target upside
- +123.5%
- High target gap
- +180.3%
- Target range width
- 110.9%
- Consensus rating
- Strong Buy
- Analysts
- 18
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Definium Therapeutics?
Definium Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $72.56.
How far are Definium Therapeutics's low and high targets from the recorded price?
The low target implies +69.4%, while the high target implies +180.3%.
How many analysts are included in Definium Therapeutics's consensus?
The verified consensus includes 18 analysts.
How is Definium Therapeutics's target upside or downside calculated?
The average target of $72.56 is divided by the recorded price of $32.47, then one is subtracted to produce +123.5%. This does not guarantee a future return.
When was Definium Therapeutics's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.